Publications by authors named "Anne Boulay"

Claim this Profile
T
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, Maddalena Marchesi, Tanya Simuni, Anne Boulay

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.
Florian Lipsmeier, Kirsten I Taylor, Ronald B Postuma, Ekaterina Volkova-Volkmar, Timothy Kilchenmann, Anne Boulay

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAI-1 production by reactive astrocytes drives tissue dysfibrinolysis in multiple sclerosis models.
Héloïse Lebas, Sylvaine Guérit, Audrey Picot, Anne Cécile Boulay, Antoine Fournier

Cell Mol Life Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Gennaro Pagano, Frank G Boess, Kirsten I Taylor, Benedicte Ricci, Brit Mollenhauer, Anne Boulay

Front Neurol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.
Usha Chakravarthy, Clare Bailey, David Brown, Peter Campochiaro, Mark Chittum, Anne Boulay

Ophthalmol Retina· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C Roloff, Martin Schreiber

EMBO Mol Med· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.
Yutaka Matsuda, Thomas Schlange, Edward J Oakeley, Anne Boulay, Nancy E Hynes

Breast Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration.
Maria Meira, Régis Masson, Igor Stagljar, Susanne Lienhard, Francisca Maurer, Anne Boulay

J Cell Sci· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Heidi A Lane, Jeanette M Wood, Paul M J McSheehy, Peter R Allegrini, Anne Boulay

Clin Cancer Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Anne Boulay, Madlaina Breuleux, Christine Stephan, Caroline Fux, Cathrin Brisken

Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Chiaki Tanaka, Terence O'Reilly, John M Kovarik, Nicholas Shand, Katharine Hazell, Anne Boulay

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mammalian target of rapamycin kinase and tumor growth inhibition.
Anne Boulay, Heidi A Lane

Recent Results Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mTOR pathway in breast cancer.
Nancy E Hynes, Anne Boulay

J Mammary Gland Biol Neoplasia· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Anne Boulay, Joelle Rudloff, Jingjing Ye, Sabine Zumstein-Mecker, Terence O'Reilly

Clin Cancer Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
Iwan Beuvink, Anne Boulay, Stefano Fumagalli, Frederic Zilbermann, Stephan Ruetz

Cell· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases.
Vincent Dive, Kumari L Andarawewa, Anne Boulay, Magdalini Matziari, Fabrice Beau

Int J Cancer· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
Anne Boulay, Sabine Zumstein-Mecker, Christine Stephan, Iwan Beuvink, Frederic Zilbermann

Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression.
Kumari L Andarawewa, Anne Boulay, Régis Masson, Carole Mathelin, Isabelle Stoll

Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors.
Fabien Alpy, Anne Boulay, Christel Moog-Lutz, Kumari L Andarawewa, Sébastien Degot

Oncogene· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis